Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Response rates ranged from 56% to 85% for several types of tumors with high HER2 expression.
The targeted therapy delayed disease progression in patients with the most common type of early-stage breast cancer.
Medicaid expansion was associated with improved two-year survival, especially for women with Stag III cancer.
The oral targeted therapy led to a 51% improvement in survival for patients with EGFR-mutated non-small-cell lung cancer.
Targeted therapies can reduce the size and number of brain metastases; patients could then have better-tolerated radiation therapy.
Genomic profiling showed patients with African ancestry had fewer actionable mutations and were less likely to qualify for immunotherapy.
The Pragmatica-Lung Study, with fewer and simpler eligibility criteria, will test whether Cyramza plus Keytruda improves survival.
The studies point to the promise of a targeted approach to acute leukemia treatment.
Treatment can improve quality of life for people with advanced breast cancer.
Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.
Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.
Adding an AKT inhibitor to fulvestrant doubled progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Rezlidhia (olutasidenib) is approved as a targeted treatment option for adults whose acute myeloid leukemia carries the IDH1 mutation.
The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.
Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.